None (BMRA) Financial Statements & Historical Data

None (BMRA) — Price $2.37

Latest reported results:

Detailed financial statements for None (BMRA): income statement, balance sheet and cash-flow summary. Track margins, debt, liquidity and profitability trends year over year with up to 20 years of history.

Biomerica, Inc. is a biomedical technology firm that invents, secures intellectual property for, produces, and globally distributes diagnostic and therapeutic solutions aimed at identifying and addressing a range of medical conditions and diseases. The company's diagnostic testing kits analyze patient samples, such as blood, urine, or stool, to pinpoint various illnesses and health complications.

Analysis Summary

None reported revenue of $4.5M in the most recent fiscal year, growing at a 5-year CAGR of -9.2%.

Balance sheet quality for BMRA: current ratio of 1.6, net debt of $1.1M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.

Income Statement (10y)

Year2017201820192020202120222023202420252026
Revenue$5.8M$5.6M$5.2M$6.7M$7.2M$18.9M$5.3M$5.4M$5.3M$4.5M
Cost of Revenue$3.8M$3.8M$3.9M$4.9M$6.8M$15.9M$4.9M$4.8M$4.8M$4.1M
Gross Profit$2.0M$1.8M$1.3M$1.8M$366285$3.0M$446000$611000$498000$362000
Research & Development$1.1M$1.4M$1.7M$1.9M$2.2M$1.8M$1.6M$1.5M$1.0M$788000
Selling, General & Admin$1.8M$1.8M$2.0M$2.3M$5.7M$5.7M$6.1M$5.5M$4.6M$4.9M
Operating Expenses$3.0M$3.2M$3.7M$4.2M$7.9M$7.5M$7.7M$7.0M$5.6M$5.7M
Operating Income-$954633-$1.5M-$2.4M-$2.4M-$7.5M-$4.5M-$7.2M-$6.4M-$5.1M-$5.3M
EBITDA-$689340-$1.2M-$2.2M-$1.9M-$7.1M-$3.9M-$6.7M-$5.6M-$4.6M-$4.9M
Interest Expense$282$37$47$9$36700000
Pre-tax Income-$908561-$1.4M-$2.4M-$2.3M-$7.4M-$4.5M-$7.1M-$5.9M-$5.0M-$3.8M
Income Tax0$31800$24237$7390$13057$23719$51000$42000$1000$23000
Net Income-$908561-$1.5M-$2.4M-$2.3M-$7.4M-$4.5M-$7.1M-$6.0M-$5.0M-$3.8M
EPS$-0.11$-0.17$-0.26$-0.23$-0.54$-0.36$-0.50$-0.36$-2.16$-1.30
EPS (Diluted)$-0.11$-0.17$-0.26$-0.23$-0.54$-0.36$-0.50$-0.36$-2.16$-1.30
Shares Outstanding (Diluted)$8.3M$8.6M$9.2M$10.2M$11.9M$12.7M$14.2M$16.8M$2.3M$2.9M

Income Statement (Quarterly)

Year2025-Q32025-Q42026-Q12026-Q2
Revenue$1.4M$1.2M$987000$875000
Gross Profit$424000$51000-$44000-$71000
Operating Income-$1.1M-$1.4M-$1.3M-$1.5M
EBITDA$107000-$1.2M-$1.2M-$1.4M
Net Income$2000-$1.3M-$1.3M-$1.1M
EPS$0.00$-0.45$-0.44$-0.37
EPS (Diluted)$0.00$-0.45$-0.44$-0.37

Balance Sheet (10y)

Year2017201820192020202120222023202420252026
Cash & Equivalents$1.2M$1.2M$686785$8.6M$4.2M$5.9M$9.7M$4.2M$2.4M$1.3M
Short-term Investments0000000000
Receivables$1.1M$799940$1.5M$1.8M$1.5M$773818$722000$947000$731000$785000
Inventory$1.7M$2.2M$2.2M$2.9M$3.2M$2.4M$2.1M$2.4M$1.5M$1.7M
Total Current Assets$4.2M$4.5M$4.5M$14.8M$9.2M$9.4M$12.8M$7.7M$4.9M$4.0M
Property, Plant & Equipment$331857$351149$351070$2.0M$1.9M$1.5M$1.2M$943000$564000$2.0M
Goodwill0000000000
Intangible Assets$174469$98923$107209$168655$294830$170000$165000$212000$228000$209000
Total Assets$5.0M$5.2M$5.2M$17.3M$11.8M$11.4M$14.5M$9.3M$5.9M$6.8M
Accounts Payable$336430$655599$999593$833412$431000$736000$344000$288000$295000$377000
Short-term Debt000000000$500000
Total Current Liabilities$528866$896808$1.3M$1.5M$1.3M$2.0M$1.9M$2.2M$1.7M$2.5M
Long-term Debt0000000000
Total Liabilities$528866$896808$1.3M$3.0M$2.6M$3.0M$2.7M$2.7M$1.8M$4.1M
Retained Earnings-$15.7M-$17.2M-$19.6M-$21.9M-$30.5M-$35.1M-$42.2M-$48.2M-$53.2M-$56.9M
Total Equity$4.5M$4.3M$4.0M$14.2M$9.2M$8.3M$11.7M$6.6M$4.1M$2.6M
Total Debt000$1.8M$1.6M$1.4M$1.1M$785000$458000$2.4M
Net Debt-$1.2M-$1.2M-$686785-$6.9M-$2.6M-$4.5M-$8.6M-$3.4M-$1.9M$1.1M
Working Capital$3.7M$3.6M$3.2M$13.3M$7.9M$7.4M$10.9M$5.5M$3.1M$1.5M

Balance Sheet (Quarterly)

Year2025-Q32025-Q42026-Q12026-Q2
Cash & Equivalents$3.1M$2.5M$1.3M$1.3M
Total Assets$6.9M$6.0M$4.9M$6.8M
Total Liabilities$1.7M$1.6M$1.6M$4.1M
Total Equity$5.2M$4.4M$3.3M$2.6M
Total Debt$373000$284000$193000$1.9M

Cash Flow (10y)

Year2017201820192020202120222023202420252026
Net Income-$908561-$1.5M-$2.4M-$2.3M-$7.4M-$4.5M-$7.1M-$6.0M-$5.0M-$3.8M
Depreciation & Amortization$219219$186601$162905$398632$375855$594821$351000$374000$400000$421000
Stock-based Compensation$21727$18473$151224$200470$1.4M$1.3M$1.2M$837000$460000$476000
Change in Working Capital-$46808$32137-$188023-$2.5M-$1.1M$2.9M-$38000-$625000$268000-$143000
Operating Cash Flow-$722858-$1.2M-$2.2M-$4.3M-$5.3M-$480532-$5.5M-$5.4M-$3.8M-$3.4M
Capital Expenditure-$96085-$130347-$171111-$118927-$295583-$170336-$78000-$115000-$37000-$1000
Acquisitions0000000000
Stock Repurchased0000-$165919-$85000-$705000000
Dividends Paid0000000000
Free Cash Flow-$818943-$1.3M-$2.4M-$4.4M-$5.5M-$650868-$5.6M-$5.5M-$3.9M-$3.4M

Cash Flow (Quarterly)

Year2025-Q32025-Q42026-Q12026-Q2
Operating Cash Flow-$268000-$991000-$1.2M-$912000
Capital Expenditure0$37000-$37000-$37000
Free Cash Flow-$268000-$954000-$1.3M-$949000
Dividends Paid0000
Stock-based Compensation$460000-$210000$135000$418000

Growth & Margins (10y)

Year2017201820192020202120222023202420252026
Revenue Growth (YoY)-3.9%-6.5%+28.7%+7.6%+162.1%-71.7%+1.4%-1.9%-16.2%
Net Income Growth (YoY)-61.3%-63.3%+2.3%-218.3%+39.2%-57.6%+16.3%+16.8%+24.1%
EPS Growth (YoY)-54.5%-52.9%+11.5%-134.8%+33.3%-38.9%+28.0%-500.0%+39.8%
Shares Change (YoY)+2.9%+7.5%+10.4%+17.3%+6.2%+11.7%+18.8%-86.3%+26.9%
FCF Growth (YoY)-59.3%-85.1%-82.9%-25.6%+88.3%-753.0%+1.4%+29.2%+11.8%
Gross Margin34.9%31.5%24.8%26.6%5.1%15.8%8.4%11.3%9.4%8.1%
Operating Margin-16.5%-26.6%-46.4%-35.9%-104.2%-24.0%-135.3%-117.6%-96.7%-119.5%
EBITDA Margin-11.9%-22.4%-42.4%-28.9%-98.0%-20.9%-126.2%-102.7%-86.1%-110.0%
Net Margin-15.7%-26.3%-46.0%-34.9%-103.4%-24.0%-133.7%-110.4%-93.6%-84.8%
FCF Margin-14.1%-23.4%-46.4%-66.0%-77.1%-3.4%-104.0%-101.1%-73.0%-76.8%
Effective Tax Rate-0.0%-2.2%-1.0%-0.3%-0.2%-0.5%-0.7%-0.7%-0.0%-0.6%

Per-Share Data (10y)

Year2017201820192020202120222023202420252026
FCF Per Share$-0.10$-0.15$-0.26$-0.43$-0.47$-0.05$-0.39$-0.33$-1.69$-1.17
Dividends Per Share$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
Shares Outstanding (Basic)$8.3M$8.6M$9.2M$10.2M$11.9M$12.7M$14.2M$16.8M$2.3M$2.9M

Financial Health

Piotroski F-Score3
Altman Z-Score-11.56

Key Ratios (10y)

Year2017201820192020202120222023202420252026
P/E-181.82-191.53-69.23-220.87-54.07-77.78-21.92-12.89-1.41-1.82
P/B36.8064.5141.6536.3437.7542.6313.2311.841.712.62
P/S28.5250.1531.8977.1748.3918.8029.0614.411.321.54
Gross Margin34.9%31.5%24.8%26.6%5.1%15.8%8.4%11.3%9.4%8.1%
Operating Margin-16.5%-26.6%-46.4%-35.9%-104.2%-24.0%-135.3%-117.6%-96.7%-119.5%
Net Margin-15.7%-26.3%-46.0%-34.9%-103.4%-24.0%-133.7%-110.4%-93.6%-84.8%

Related companies: ALZN · CELZ · HSCS · IINN · LFWD · LUCY · PAVM

More sections of BMRA: Overview · Valuation · Statistics · Estimates · Technical · Ownership · News · Events

Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks